Eyam Vaccine and Immunotherapeutics (EYAM), a next-generation vaccine biotechnology company, announced today an agreement with Veristat, a scientific-minded, global clinical research organization (CRO), to plan and coordinate clinical trials of their vaccine program against SARS-CoV-2.
MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce a Letter of Intent (“LOI”) with Eyam Vaccines and Immunotherapeutics (“Eyam“).
B.C.’s ‘world-class’ biotech sector plays key role in developing COVID-19 treatments and vaccines May [...]
Messenger RNA vaccines (Pfizer and Moderna) are the most effective of the suite of vaccines being made globally and are the most commonly used in B.C.
A Canadian company has announced that it is doing preclinical studies of unique COVID-19 vaccine candidates to target variant strains.
Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. James LaBelle, Chief Medical Officer of Ripplenami, joined EYAM’s board of directors.
Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. James LaBelle, Chief Medical Officer of Ripplenami, joined EYAM’s board of directors.
Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. James LaBelle, Chief Medical Officer of Ripplenami, joined EYAM’s board of directors.
Today, Eyam announced the appointment of Dr. Lyle Oberg to the Board of Directors of Eyam Vaccines and Immunotherapeutics.
Today, Eyam announced the addition of Mr. Dave Richardson as our newest advisory board member.
